Valuation: AAP IMPLANTATE

Market Cap 2.35Cr 2.64Cr 2.2Cr 2Cr 3.76Cr 254.63Cr 3.81Cr 27Cr 10Cr 129.87Cr 9.92Cr 9.7Cr 417.67Cr P/E 2024
-3.6x
P/E 2025 -7.58x
Enterprise Value 2.32Cr 2.61Cr 2.17Cr 1.98Cr 3.71Cr 251.23Cr 3.76Cr 26Cr 10Cr 128.13Cr 9.79Cr 9.57Cr 412.09Cr EV / Sales 2024
1.32x
EV / Sales 2025 1.56x
Free-Float
38.19%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 64 01/05/2019
Director of Finance/CFO - 19/08/2026
Chief Operating Officer - 19/08/2026
Director TitleAgeSince
Director/Board Member 70 01/01/2016
Chairman 55 04/07/2019
Director/Board Member 50 01/11/2021
Change 5-day change 1-year change 3-year change Capi.($)
-2.17%-6.57%-27.81%-0.17% 17TCr
+0.17%-3.20%-9.24%+10.31% 11TCr
-0.88%-0.16%-26.16%-0.11% 11TCr
-0.69%-3.57%-47.61%-12.45% 7.6TCr
+3.17%-0.80%-0.88%+72.13% 5.73TCr
-0.52%-2.44%-4.86%-31.12% 4.88TCr
+3.44%+7.90%+19.12%+59.15% 5.02TCr
-0.85%-0.82%-18.96%+18.41% 4.11TCr
-0.07%-1.71%+28.15%-7.58% 3.26TCr
Average +0.12%-1.46%-9.81%+12.06% 7.7TCr
Weighted average by Cap. -0.38%-2.07%-16.38%+9.01%

Financials

2024 2025
Net sales 1.22Cr 1.37Cr 1.14Cr 1.04Cr 1.95Cr 132.18Cr 1.98Cr 14Cr 5.33Cr 67Cr 5.15Cr 5.04Cr 216.82Cr 1.25Cr 1.4Cr 1.17Cr 1.06Cr 2Cr 135.26Cr 2.03Cr 14Cr 5.46Cr 69Cr 5.27Cr 5.15Cr 221.87Cr
Net income -36.3L -40.81L -33.9L -30.93L -58.02L -39Cr -58.87L -4.1Cr -1.59Cr -20Cr -1.53Cr -1.5Cr -64Cr -25.85L -29.06L -24.14L -22.02L -41.32L -28Cr -41.93L -2.92Cr -1.13Cr -14Cr -1.09Cr -1.07Cr -46Cr
Net Debt -11.01L -12.38L -10.28L -9L -17.6L -12Cr -17.86L -1.24Cr -48.12L -6.08Cr -46.46L -45.44L -20Cr -3L -4L -3L -3L -5L -3.4Cr -5L -35.45L -13.72L -1.73Cr -13.25L -12.96L -5.58Cr
Logo AAP IMPLANTATE
aap Implantate AG is a Germany-based provider of medical devices for human muscular and skeletal systems. The Company focuses on trauma and biomaterials products for orthopedics. The Biomaterials portfolio comprises bone substitutes for the filling of aseptic bone defects, bone cements and accessories for the application in arthroplasty, bone cements and accessories for the application in vertebroplasty and kyphoplasty. The trauma portfolio includes a wide range of cannulated screws, standard plates and screws for miniature, small and large bone fragments, among others . It also develops LOQTEQ, a technology that allows for fracture compression with subsequent locking fixation in one surgical step. The Company operates a network of distributors in more than 60 countries, and cooperates directly with physicians and hospital customers.
Employees
-